Friday 6 November 2026 Export AXSM’s income statement to Excel — free account

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.

Revenue: +51.9%
EPS: +73.9%
Free cash flow: −1,078.3%
Total debt: +4.04%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

132.13 2.33 +1.80%

Follow AXSM

Alert me

Market cap: $6.8B
P/E: 0.0×
Fwd P/E: −49.2×
Dividend yield: —
F-score: 5/9
Altman Z: 6.91
Beneish M: −2.53
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Axsome Therapeutics, Inc. (AXSM) revenue by segment, product and region

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022
Product Sales	634 99.26%	382 98.96%	202 74.82%	50 100.00%
Milestone Revenue	5 0.74%	4 1.04%	2 0.89%	—
License Fee	—	—	66 24.29%	—
Revenue	638	386	271	50

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Auvelity commercial channel coverage	Q3 FY2026	82.0%	75.0%	—
Auvelity government channel coverage	Q3 FY2026	100.0%	100.0%	—
Auvelity payer coverage across all channels	Q3 FY2026	89.0%	85.0%	—
Auvelity prescriptions written	Q3 FY2026	302.0K	209.0K	+44.50%
Sunosi commercial channel coverage	Q3 FY2026	97.0%	95.0%	—
Sunosi government channel coverage	Q3 FY2026	59.0%	60.0%	—
Sunosi payer coverage across all channels	Q3 FY2026	82.0%	83.0%	—
Sunosi prescriptions written in the U.S.	Q3 FY2026	64.4K	53.0K	+21.51%
Symbravo prescriptions reported	Q3 FY2026	25.0K	5.0K	+400.00%

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024
Auvelity commercial channel coverage	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Auvelity government channel coverage	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Auvelity payer coverage across all channels	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Auvelity prescriptions written	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Sunosi commercial channel coverage	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Sunosi government channel coverage	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Sunosi payer coverage across all channels	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Sunosi prescriptions written in the U.S.	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Symbravo prescriptions reported	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Axsome Therapeutics, Inc. (AXSM) revenue by segment, product and region

Revenue by product or service $m

Operating figures as reported in each quarter’s results release or filing

Stockrow Weekly